These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10707032)

  • 1. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.
    Charles MA; Eschwège E; Grandmottet P; Isnard F; Cohen JM; Bensoussan JL; Berche H; Chapiro O; André P; Vague P; Juhan-Vague I; Bard JM; Safar M
    Diabetes Metab Res Rev; 2000; 16(1):2-7. PubMed ID: 10707032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.
    Fontbonne A; Charles MA; Juhan-Vague I; Bard JM; André P; Isnard F; Cohen JM; Grandmottet P; Vague P; Safar ME; Eschwège E
    Diabetes Care; 1996 Sep; 19(9):920-6. PubMed ID: 8875083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance.
    Fontbonne A; André P; Eschwège E
    Diabete Metab; 1991 May; 17(1 Pt 2):249-54. PubMed ID: 1936485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
    Bard JM; Charles MA; Juhan-Vague I; Vague P; André P; Safar M; Fruchart JC; Eschwege E;
    Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):407-14. PubMed ID: 11231921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.
    Charles MA; Morange P; Eschwège E; André P; Vague P; Juhan-Vague I
    Diabetes Care; 1998 Nov; 21(11):1967-72. PubMed ID: 9802752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
    Kosegawa I; Katayama S; Kikuchi C; Kashiwabara H; Negishi K; Ishii J; Inukai K; Oka Y
    Hypertens Res; 1996 Mar; 19(1):37-41. PubMed ID: 8829822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.
    Dorella M; Giusto M; Da Tos V; Campagnolo M; Palatini P; Rossi G; Ceolotto G; Felice M; Semplicini A; Del Prato S
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1568-74. PubMed ID: 8636369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.
    Gudbjörnsdottir S; Friberg P; Elam M; Attvall S; Lönnroth P; Wallin BG
    Blood Press; 1994 Nov; 3(6):394-403. PubMed ID: 7704288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and metoprolol CR treatment in non-obese men.
    Landin K; Tengborn L; Smith U
    J Intern Med; 1994 Apr; 235(4):335-41. PubMed ID: 8151265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.
    Snorgaard O; Køber L; Carlsen J
    J Intern Med; 1997 Nov; 242(5):407-12. PubMed ID: 9408071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
    Worsley R; Jane F; Robinson PJ; Bell RJ; Davis SR
    Climacteric; 2015 Apr; 18(2):270-7. PubMed ID: 25333776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
    McNulty SJ; Ur E; Williams G;
    Diabetes Care; 2003 Jan; 26(1):125-31. PubMed ID: 12502668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
    Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
    J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial.
    He H; Zhao Z; Chen J; Ni Y; Zhong J; Yan Z; Li Y; Liu D; Pletcher MJ; Zhu Z
    J Hypertens; 2012 Jul; 30(7):1430-9. PubMed ID: 22525206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.